| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Tumor Immunology Group, Department of Medicine, University of Western Australia and Western Australian Institute of Medical Research, Perth, Australia;
Immunology Division, Walter and Eliza Hall Institute, Parkville, Australia; and
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599
Cross-presentation of cell-bound Ags from established, solid tumors to CD8 cells is efficient and likely to have a role in determining host response to tumor. A number of investigators have predicted that when tumor Ags are derived from apoptotic cells either no response, due to Ag "sequestration," or CD8 cross-tolerance would ensue. Because the crucial issue of whether this happens in vivo has never been addressed, we induced apoptosis of established hemagglutinin (HA)-transfected AB1 tumors in BALB/c mice using the apoptosis-inducing reagent gemcitabine. This shrank the tumor by 
80%. This induction of apoptosis increased cross-presentation of HA to CD8 cells yet neither gross deletion nor functional tolerance of HA-specific CD8 cells were observed, based on tetramer analysis, proliferation of specific CD8 T cells, and in vivo CTL activity. Interestingly, apoptosis primed the host for a strong antitumor response to a second, virus-generated HA-specific signal in that administration of an HA-expressing virus after gemcitabine administration markedly decreased tumor growth compared with viral administration without gemcitabine. Thus tumor cell apoptosis in vivo neither sequesters tumor Ags nor cross-tolerizes tumor-specific CD8 cells. This observation has fundamental consequences for the development of tumor immunotherapy protocols and for understanding T cell reactivity to tumors and the in vivo immune responses to apoptotic cells.
This article has been cited by other articles:
|
|
 |
|
  N. Iida, Y. Nakamoto, T. Baba, K. Kakinoki, Y.-Y. Li, Y. Wu, K. Matsushima, S. Kaneko, and N. Mukaida Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice J. Leukoc. Biol., October 1, 2008; 84(4): 1001 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Kim, B. K. Choi, K. H. Kim, S. W. Kang, and B. S. Kwon Combination Therapy with Cisplatin and Anti-4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced Nephrotoxicity Cancer Res., September 15, 2008; 68(18): 7264 - 7269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Hunder, H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, and C. Yee Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 N. Engl. J. Med., June 19, 2008; 358(25): 2698 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Anraku, K. S. Cunningham, Z. Yun, M.-S. Tsao, L. Zhang, S. Keshavjee, M. R. Johnston, and M. de Perrot Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 823 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. VanOosten and T. S. Griffith Activation of Tumor-Specific CD8+ T Cells after Intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide Combination Therapy Cancer Res., December 15, 2007; 67(24): 11980 - 11990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Bauer, F Bauernfeind, A Sterzik, M Orban, M Schnurr, H A Lehr, S Endres, A Eigler, and M Dauer Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut, September 1, 2007; 56(9): 1275 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Ko, Y.-J. Kim, Y.-S. Kim, W.-S. Chang, S.-Y. Ko, S.-Y. Chang, S. Sakaguchi, and C.-Y. Kang A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model Cancer Res., August 1, 2007; 67(15): 7477 - 7486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Manning, J. G.M. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism Clin. Cancer Res., July 1, 2007; 13(13): 3951 - 3959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. A. Hasan, C. Caux, I. Perrot, A.-C. Doffin, C. Menetrier-Caux, G. Trinchieri, M. Tommasino, and J. Vlach Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs PNAS, May 8, 2007; 104(19): 8047 - 8052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Beltran, A. K. Ghosh, and S. Basu Immunotherapy of Tumors with Neuroimmune Ligand Capsaicin J. Immunol., March 1, 2007; 178(5): 3260 - 3264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gamrekelashvili, C. Kruger, R. von Wasielewski, M. Hoffmann, K. M. Huster, D. H. Busch, M. P. Manns, F. Korangy, and T. F. Greten Necrotic Tumor Cell Death In Vivo Impairs Tumor-Specific Immune Responses J. Immunol., February 1, 2007; 178(3): 1573 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zhang, N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y.-X. Fu, R. R. Weichselbaum, D. A. Rowley, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells J. Exp. Med., January 22, 2007; 204(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Kang, J. H. Lee, C. K. Song, H. D. Han, B. C. Shin, S. I. Pai, C.-F. Hung, C. Trimble, J.-S. Lim, T. W. Kim, et al. Epigallocatechin-3-Gallate Enhances CD8+ T Cell-Mediated Antitumor Immunity Induced by DNA Vaccination Cancer Res., January 15, 2007; 67(2): 802 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, A. Dutuor, L. Tao, X. Fu, and X. Zhang Virotherapy with a Type 2 Herpes Simplex Virus-Derived Oncolytic Virus Induces Potent Antitumor Immunity against Neuroblastoma Clin. Cancer Res., January 1, 2007; 13(1): 316 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Hargadon, C. C. Brinkman, S. L. Sheasley-O'Neill, L. A. Nichols, T. N. J. Bullock, and V. H. Engelhard Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes J. Immunol., November 1, 2006; 177(9): 6081 - 6090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Plesa, P. M. McKenna, M. J. Schnell, and L. C. Eisenlohr Immunogenicity of cytopathic and noncytopathic viral vectors. J. Virol., July 1, 2006; 80(13): 6259 - 6266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. van der Most, A. Currie, B. W.S. Robinson, and R. A. Lake Cranking the Immunologic Engine with Chemotherapy: Using Context to Drive Tumor Antigen Cross-Presentation towards Useful Antitumor Immunity Cancer Res., January 15, 2006; 66(2): 601 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Preynat-Seauve, P. Schuler, E. Contassot, F. Beermann, B. Huard, and L. E. French Tumor-Infiltrating Dendritic Cells Are Potent Antigen-Presenting Cells Able to Activate T Cells and Mediate Tumor Rejection J. Immunol., January 1, 2006; 176(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Casares, M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, N. Chaput, E. Schmitt, A. Hamai, S. Hervas-Stubbs, M. Obeid, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J. Exp. Med., December 19, 2005; 202(12): 1691 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Correale, M. G. Cusi, K. Y. Tsang, M. T. Del Vecchio, S. Marsili, M. L. Placa, C. Intrivici, A. Aquino, L. Micheli, C. Nencini, et al. Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients J. Clin. Oncol., December 10, 2005; 23(35): 8950 - 8958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gillet, B. Dewals, F. Farnir, L. de Leval, and A. Vanderplasschen Bovine Herpesvirus 4 Induces Apoptosis of Human Carcinoma Cell Lines In vitro and In vivo Cancer Res., October 15, 2005; 65(20): 9463 - 9472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Singh, M. E. Dominiecki, E. M. Jaffee, and Y. Paterson Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse J. Immunol., September 15, 2005; 175(6): 3663 - 3673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Broomfield, A. Currie, R. G. van der Most, M. Brown, I. van Bruggen, B. W.S. Robinson, and R. A. Lake Partial, but not Complete, Tumor-Debulking Surgery Promotes Protective Antitumor Memory when Combined with Chemotherapy and Adjuvant Immunotherapy Cancer Res., September 1, 2005; 65(17): 7580 - 7584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Otahal, S. C. Hutchinson, L. M. Mylin, M. J. Tevethia, S. S. Tevethia, and T. D. Schell Inefficient Cross-Presentation Limits the CD8+ T Cell Response to a Subdominant Tumor Antigen Epitope J. Immunol., July 15, 2005; 175(2): 700 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Correale*, M. G. Cusi, M. T. Del Vecchio, A. Aquino, S. Prete, K. Y. Tsang, L. Micheli, C. Nencini, M. La Placa*, F. Montagnani*, et al. Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro J. Immunol., July 15, 2005; 175(2): 820 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. J. J. Hegmans, A. Hemmes, J. G. Aerts, H. C. Hoogsteden, and B. N. Lambrecht Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate-pulsed Dendritic Cells Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1168 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Liadis, K. Murakami, M. Eweida, A. R. Elford, L. Sheu, H. Y. Gaisano, R. Hakem, P. S. Ohashi, and M. Woo Caspase-3-Dependent {beta}-Cell Apoptosis in the Initiation of Autoimmune Diabetes Mellitus Mol. Cell. Biol., May 1, 2005; 25(9): 3620 - 3629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Casati, V. S. Zimmermann, F. Benigni, M. T. S. Bertilaccio, M. Bellone, and A. Mondino The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration J. Immunol., March 15, 2005; 174(6): 3317 - 3325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Demaria, F. R. Santori, B. Ng, L. Liebes, S. C. Formenti, and S. Vukmanovic Select forms of tumor cell apoptosis induce dendritic cell maturation J. Leukoc. Biol., March 1, 2005; 77(3): 361 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. D. van Mierlo, Z. F. H. M. Boonman, H. M. H. Dumortier, A. Th. den Boer, M. F. Fransen, J. Nouta, E. I. H. van der Voort, R. Offringa, R. E. M. Toes, and C. J. M. Melief Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication J. Immunol., December 1, 2004; 173(11): 6753 - 6759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Stumbles, R. Himbeck, J. A. Frelinger, E. J. Collins, R. A. Lake, and B. W. S. Robinson Cutting Edge: Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation J. Immunol., November 15, 2004; 173(10): 5923 - 5928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Matsumoto, G. R. Leggatt, J. Zhong, X. Liu, R. L. de Kluyver, T. Peters, G. J. P. Fernando, A. Liem, P. F. Lambert, and I. H. Frazer Impaired Antigen Presentation and Effectiveness of Combined Active/Passive Immunotherapy for Epithelial Tumors J Natl Cancer Inst, November 3, 2004; 96(21): 1611 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Thomas, L. M. Santarsiero, E. R. Lutz, T. D. Armstrong, Y.-C. Chen, L.-Q. Huang, D. A. Laheru, M. Goggins, R. H. Hruban, and E. M. Jaffee Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients J. Exp. Med., August 2, 2004; 200(3): 297 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chakraborty, S. I. Abrams, C. N. Coleman, K. Camphausen, J. Schlom, and J. W. Hodge External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing Cancer Res., June 15, 2004; 64(12): 4328 - 4337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Nguewa, M. A. Fuertes, C. Alonso, and J. M. Perez Pharmacological Modulation of Poly(ADP-ribose) Polymerase-Mediated Cell Death: Exploitation in Cancer Chemotherapy Mol. Pharmacol., November 1, 2003; 64(5): 1007 - 1014. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Nowak, B. W. S. Robinson, and R. A. Lake Synergy between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors Cancer Res., August 1, 2003; 63(15): 4490 - 4496. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
